Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary10/14/2011
MISGAV, Israel & SAN FRANCISCO, Oct 14, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) , the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces an update to its previously
Toggle Summary09/09/2011
Webcast Scheduled for September 13, 2011 at 4:05 p.m. Eastern Time MISGAV, Israel & SAN FRANCISCO, Sep 09, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic
Toggle Summary09/09/2011
MISGAV, Israel & SAN FRANCISCO, Sep 09, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announced today the
Toggle Summary08/30/2011
MISGAV, Israel & SAN FRANCISCO, Aug 30, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announced today that
Toggle Summary08/12/2011
MISGAV, Israel & SAN FRANCISCO, Aug 12, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported
Toggle Summary08/10/2011
MISGAV, Israel & SAN FRANCISCO, Aug 10, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) the ("Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported that
Toggle Summary07/06/2011
MISGAV, Israel and VIENNA, Va., Jul 06, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) announces an extension of its agreement with Baxter Healthcare Corporation for the joint development of the Factor VIII Biopump. Under the extension, confirmatory studies will be
Toggle Summary07/05/2011
Experienced Biotech Executive Provides Strategic Management and Manufacturing Expertise MISGAV, Israel & SAN FRANCISCO, Jul 05, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) today announced that Clarence "Butch" Dellio has been named to the position of Chief
Toggle Summary06/24/2011
MISGAV, Israel & VIENNA, Va., Jun 24, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) announces that the NYSE Amex contacted the Company yesterday and, in accordance with its usual practice, requested that the Company issue a press release regarding the increased
Toggle Summary06/08/2011
MISGAV, Israel & VIENNA, Va., Jun 08, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) today announced that Isaac Blech, age 61, a leading biotechnology entrepreneur and investor, has joined the Company's Board of Directors. Mr.